# Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation

> **NCT02159248** · PHASE1 · WITHDRAWN · sponsor: **Orlando Health, Inc.**

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Tolfenamic acid + gemcitabine + radiation

## Key facts

- **NCT ID:** NCT02159248
- **Lead sponsor:** Orlando Health, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-03
- **Primary completion:** 2017-08
- **Final completion:** 2019-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study closed prior to enrolling any participants.
- **Last updated:** 2015-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02159248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02159248, "Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02159248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*